We submit here a proposal for renewal of the Pharmacogenomics of Arrhythmia Therapy (PAT) node of the PGRN. The studies we propose combine candidate, genome-wide, and targeting resequencing approaches to identify the genomic basis for arrhythmia drug response phenotypes of major public health importance. In addition, each Specific Aim includes a major focus on multi-institutional accumulation of large numbers of patients with well-defined drug response phenotypes. Studies In Specific Aim 1 further define the genomic basis underlying susceptibility to drug-induced long QT-related arrhythmias, a continuing challenge In clinical drug use and In drug development.
In Specific Aim 2, we build on previous work to prospectively assess the relationships among drug response, genotypes, and clinical endophenotypes in patients with atrial fibrillation (AF). While AF therapy often includes warfarin anticoagulation whose major complication is bleeding, pharmacogenomic studies of warfarin response to date have focused on determinants of dose.
In Specific Aim 3, we will identify a large set of cases of major warfarin-related bleeding in BioVU, our DNA repository linked to de-identified electronic medical records, and undertake a case-control study of the genomic determinants of this complication. We include here two proposals for network resources: (1) PGPop (PharmacoGenomic discovery and replication in very large patient Populations) that brings together multiple healthcare system-based nodes, including BioVU, that each Include extensive drug response phenotypes and extant or planned large DNA collections. PGPop will serve as a """"""""real-world"""""""" platform for pharmacogenomic discovery;one initial project will be generation of a replication set for warfarin-related bleeding. (2) P-STAR (PGRN Statistical Analysis Resource), that will provide statistical support to PGRN sites and develop advanced methods in the field. These studies build on progress within our own site, across PGRN, and reach out beyond the network to develop expanded populations and new tools to enable application of pharmacogenetic knowledge to clinical care.

Public Health Relevance

We build here on previous progress to understand the genomic basis of variability in drug response among patients with cardiac arrhythmias, a continuing public health problem. The methods we adopt have the potential not only to affect our understanding of arrhythmia pharmacogenomics but also to more generally refine and expand our approaches to the problem of variable drug responses.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program--Cooperative Agreements (U19)
Project #
2U19HL065962-10
Application #
7868524
Study Section
Special Emphasis Panel (ZRG1-GGG-M (52))
Program Officer
Paltoo, Dina
Project Start
2000-04-01
Project End
2015-06-30
Budget Start
2010-09-01
Budget End
2011-06-30
Support Year
10
Fiscal Year
2010
Total Cost
$3,580,042
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Rhoades, Seth D; Bastarache, Lisa; Denny, Joshua C et al. (2018) Pulling the covers in electronic health records for an association study with self-reported sleep behaviors. Chronobiol Int 35:1702-1712
Choi, Seung Hoan; Weng, Lu-Chen; Roselli, Carolina et al. (2018) Association Between Titin Loss-of-Function Variants and Early-Onset Atrial Fibrillation. JAMA 320:2354-2364
Mosley, Jonathan D; Feng, QiPing; Wells, Quinn S et al. (2018) A study paradigm integrating prospective epidemiologic cohorts and electronic health records to identify disease biomarkers. Nat Commun 9:3522
Bergmeijer, Thomas O; Reny, Jean-Luc; Pakyz, Ruth E et al. (2018) Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). Am Heart J 198:152-159
Galligan, James J; Wepy, James A; Streeter, Matthew D et al. (2018) Methylglyoxal-derived posttranslational arginine modifications are abundant histone marks. Proc Natl Acad Sci U S A 115:9228-9233
Gamazon, Eric R; Segrè, Ayellet V; van de Bunt, Martijn et al. (2018) Using an atlas of gene regulation across 44 human tissues to inform complex disease- and trait-associated variation. Nat Genet 50:956-967
Luzum, J A; Pakyz, R E; Elsey, A R et al. (2017) The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems. Clin Pharmacol Ther 102:502-510
Hall, Molly A; Wallace, John; Lucas, Anastasia et al. (2017) PLATO software provides analytic framework for investigating complexity beyond genome-wide association studies. Nat Commun 8:1167
Karnes, Jason H; Bastarache, Lisa; Shaffer, Christian M et al. (2017) Phenome-wide scanning identifies multiple diseases and disease severity phenotypes associated with HLA variants. Sci Transl Med 9:
Chhibber, A; French, C E; Yee, S W et al. (2017) Transcriptomic variation of pharmacogenes in multiple human tissues and lymphoblastoid cell lines. Pharmacogenomics J 17:137-145

Showing the most recent 10 out of 242 publications